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The dysfunction of pancreatic β-cell and the reduction in β-cell mass are the decisive events in the progression of type 2 diabetes.
There is increasing evidence that cytokines play important roles in the procedure of β- c e l lf a i l u r e .C yt o k i n e s ,s u c ha sI L - 1 β,I F N - γ,
TNF-α, leptin, resistin, adiponectin, and visfatin, have been shown to diversely regulate pancreatic β-cell function. Recently, islet-
derived cytokine PANcreatic DERived factor (PANDER or FAM3B) has also been demonstrated to be a regulator of islet β-cell
function. The change in cytokine proﬁle in islet and plasma is associated with pancreatic β-cell dysfunction and apoptosis. In this
paper, we summarize and discuss the recent studies on the eﬀects of certain important cytokines on pancreatic β-cell function.
The imbalance in deleterious and protective cytokines plays pivotal roles in the development and progression of pancreatic β-cell
dysfunction under insulin-resistant conditions.
1.Introduction
Diabetes is a chronic disease that occurs when pancreatic
islets fail to produce suﬃcient insulin and/or the sensitivity
of glucose-metabolizing tissues to insulin decreases. Chronic
hyperglycemia may lead to serious damage to many organs
and cause the impairment of insulin production and action.
The mechanisms of islet β cell failure are diﬀerent in the
progression of type 1 and type 2 diabetes. In the progression
of type 1 diabetes, pancreatic islet β cells are mainly destruc-
ted by autoimmune-mediated apoptosis, leading to the loss
of insulin production. Inﬂammatory cytokines play crucial
roles in this process [1]. In the progression of type 2 diabetes,
the failure of β-cell function and β-cell mass reduction are
predominantly associated with the increase in circulating
cytokines and in free fatty acids (FFAs) and with persistent
hyperglycemia [2]. Chronic exposure of β cell to these medi-
ators induces excessive production of reactive oxygen species
(ROS) and activation of caspases, which inhibit insulin
secretion and promote apoptosis of pancreatic β cells [3].
In the past decades, it had been well established that
inﬂammatory cytokines including IL-1β,T N F - α,a n dI F N -
γ play a critical role in the pathogenesis of type 1 diabetes.
At the early stage of type 1 diabetes, some immune cells such
as lymphocytes and macrophages inﬁltrate into the islets of
pancreas and secrete inﬂammatory cytokines, resulting in
high concentrations of cytokines within islets [1]. Chronic
exposure of β cells to IL-1β,T N F - α,a n dI F N - γ ﬁnally
induces islet dysfunction and β cell apoptosis. Since the
discovery of leptin and other adipose-derived hormones, it
has been realized that adipose is an endocrine organ besides
being the main energy reservation tissue [4]. Adipocytokine
is a general term of adipose-speciﬁc cytokines, such as
leptin, resistin, adiponectin, visfatin, and omentin, and
nonadipose-speciﬁc cytokines such as IL-6, IL-1β,a n dT N F -
α [5, 6]. Cytokines including IL-1β, leptin, resistin, and
adiponectin have been shown to play important roles in
the development of pancreatic β-cell dysfunction and type
2 diabetes. Recently, PANcreatic DERived factor (PANDER,
FAM3B), a cytokine-like protein, had been shown to be a
regulator of pancreatic β-cell function [7–9].
Depending on their roles in regulating pancreatic β-
cell function, some cytokines are protective, others can be
detrimental. For instance, chronic exposure of islets to some
cytokines such as IL-1β,I F N - γ,T N F - α, and resistin inhibits
insulin secretion and induces apoptosis of β cells. Other2 International Journal of Endocrinology
cytokines such as adiponectin and visfatin exert protective
eﬀects on pancreatic β cell function. In addition to circu-
lating cytokines, islets also produce a variety of cytokines
in response to physiologic and pathologic stimuli, and these
locallyproducedcytokinesplayimportantrolesinregulation
of pancreatic β-cell function as well [10, 11]. To maintain the
normal pancreatic β-cell function, the deleterious and pro-
tective cytokines need to be balanced. The abnormal change
in cytokine proﬁle in islet and plasma is associated with
pancreatic β-cell dysfunction and type 2 diabetes [10, 12]. In
this paper, recent ﬁndings regarding the eﬀects of cytokines
including IL-1β,I F N - γ,T N F - α, leptin, resistin, adiponectin,
visfatin, and PANDER on pancreatic β-cell dysfunction and
type 2 diabetes will be summarized and discussed.
2.IL-1β/IFN-γ/TNF-α
IL-1β-mediated pancreatic β-cell dysfunction and apoptosis
are involved in the pathogenesis of pancreatic β-cell dys-
function and type 2 diabetes. Short-time pretreatment of
pancreatic β cells with IL-1β,I F N - γ,a n dT N F - α,a l o n eo r
in combination, results in signiﬁcant inhibition of insulin
secretion in the absence or presence of stimulatory glucose
concentration [13, 14]. Chronic exposure of pancreatic β
cell to IL-1β activates the expression of inducible nitric
oxide synthase (iNOS) and results in excessive production
of nitric oxide (NO), which interferes with electron transfer,
inhibits ATP synthesis in mitochondria, and induces the
expression of proinﬂammatory genes [15, 16] .Ad e c r e a s ei n
cellular ATP content inhibits insulin secretion and results in
cell dysfunction. It has been widely accepted that Nuclear
Transcription Factor-κB( N F - κB) predominantly mediates
IL-1β- or other cytokine-induced activation of iNOS in
pancreatic β cells [17–19]. Persistent activation of NF-κB
induces a sustained decrease in expression of β-cell-speciﬁc
proteinsincludinginsulin,GLUT-2,andPDX-1concomitant
with an increase in iNOS expression [20]. Sulforaphane,
radix clematidis, guggulsterone, or other molecules has been
shown to protect pancreatic β cell from apoptosis induced by
cytokines including IL-1β and IFN-γ via inhibition of NF-κB
activation and iNOS expression [21–23]. Overexpression of
MnSOD also protects β cells from IL-1β or other cytokine-
induced apoptosis by repressing NF-κB activation and iNOS
expression[24].NF-κB1(p50)-deﬁcientmicearenotsuscep-
tible to multiple low-dose streptozotocin-induced diabetes
[25]. In contrast to persistent activation, transient activation
of NF-κB may be beneﬁcial to insulin secretion from
pancreatic islets at the early stage of cytokine stress [20, 26].
However, cytokines including IL-1β,I F N - γ,a n dT N F - α have
also been reported to inhibit insulin secretion and induce
apoptosis of β cell via iNOS-independent pathway [27, 28].
Endoplasmic reticulum (ER) stress-mediated apoptosis has
beenproposedasanadditionalimportantmechanismforIL-
1β-mediated pancreatic β cell death. Pretreatment of β cells
(primary islet β cells and MIN6 cells) with 4-Phenyl butyric
acid (PBA) to alleviate ER stress signiﬁcantly reduces IL-
1β-induced cell apoptosis [29]. PBA may partially alleviate
IL-1β’s deleterious eﬀect on β cell by depleting ER Ca2+
and activating c-Jun NH(2)-terminal kinase (JNK) signaling
pathway [29]. IL-1β and IFN-γ in combination markedly
decrease the sarcoendoplasmic reticulum pump Ca2+ ATPase
2b(SERCA2b)proteinexpressionanddepleteERCa2+ stores
by stimulating NO synthesis, which subsequently activates
theERstresspathway[30].IL-1β plusIFN-γ alsoupregulates
the BH3-only protein, DP5, which induces ER stress and
consequently triggers β cell apoptosis [31]. Maedler and
colleagues reported in 2002 that incubation of human islets
with high concentration of glucose (33.3mM) for 20 hours
signiﬁcantly induced IL-1β production and locally produced
IL-1β exerted deleterious eﬀects on human islet function
[32]. This suggests that islet-produced IL-1β maybe be
involved in glucotoxicity on islet β cell. In support, IL-1β
expression is shown to be increased in islets from type 2
diabetic patients [33]. However, Welsh and colleague report
thatstimulationwith11and28mMglucosefor48hoursor7
days fails to aﬀect the expression of IL-1 receptor antagonist
(IL-1ra), Fas, IkB-α, or monocyte chemoattractant protein
(MCP-1)inhumanislets.Theauthorsfurthershowthathigh
glucosefailstoinduceIL-1β productioninhumanislets[34].
Overall,althoughwhetherglucoseregulatestheexpressionof
IL-1β or IL-1ra in human islets remains controversial [34], it
has been well established that local and/or systemic IL-1β’s
play an important role in the progression of islet dysfunction
and β cell apoptosis in type 2 diabetes. Adenoviral-mediated
overexpression of IL-1ra increases β-cell replication in rat
pancreatic islets [35]. IL-1Ra treatment ameliorates hyper-
glycemia of high-fat-diet- (HFD-) induced mice. In vitro,
IL-1ra protects islets of HFD-treated mice from β-cell apop-
tosis, induces β-cell proliferation, and improves glucose-
stimulated insulin secretion [36]. Consistently, administra-
tionofIL-1β-neutralizingantibodyfor13weekssigniﬁcantly
reduces glycated hemoglobin (0.45%), serum proinsulin (2.1
± 0.2 versus 4.8 ± 0.9ng/mL), and insulin levels (3.6 ±
0.5 versus 5.2 ± 1.4ng/mL), and improves islet function
in HFD-induced diabetic mice [37]. Treatment of diabetic
GK rats with IL-1ra attenuates hyperglycemia, reduces the
proinsulin/insulin ratio, and improves insulin sensitivity. In
addition, the expression of islet-derived proinﬂammatory
cytokines including IL-1β and TNF-α is reduced by IL-
1ra treatment with amelioration of islet inﬂammation [38,
39]. IL-1ra also protects human islets from IL-1β-induced
productionofNO,impairmentinglucose-stimulatedinsulin
secretion, and apoptosis of β cells [15, 40]. Pioglitazone also
protects human islet β cells from IL-1β-induced apoptosis by
blocking NF-κBa ct i v a t i o n[ 41]. Patients with type 2 diabetes
receiving subcutaneously a daily dose of 100mg of anakinra,
arecombinanthumanIL-1ra,for13weeksshowasigniﬁcant
decrease in glycated hemoglobin level and fasting blood
glucose, ratio of serum proinsulin to insulin, and IL-6 and
C-reactive protein levels while show an increase in serum C-
peptide level [42, 43]. Clearly, these studies in animal models
and human or human islets strongly suggest that blockade of
IL-1β signaling pathway will improve β-cell dysfunction and
ameliorate hyperglycemia.
It has been previously reported that the use of TNF-α or
IFN-γ alone fails to induce β cell apoptosis, whereas in com-
bination they markedly induce β cell death. Interferon reg-
ulatory factor 1 (IRF-1) may mediate IFN-γ/TNF-α-inducedInternational Journal of Endocrinology 3
apoptosis of pancreatic β cells. IFN-γ induces the expression
of IRF-1, which makes insulinoma cells susceptible to TNF-
α [44]. X-linked inhibitor of apoptosis protein (XIAP), an
antiapoptotic protein, can protect pancreatic β cells from
being damaged by IFN-γ/TNF-α toxicity. Overexpression
of XIAP abrogates TNF-α induced apoptosis of insulin-
secreting MIN6N8 cells via inhibition of caspase activation,
whereas downregulation of XIAP augments MIN6N8 cell
apoptosis induced by TNF-α and IFN-γ [45]. Moreover, the
amplitude of high-voltage-activated Ca2+ currents has been
demonstrated to be increased in MIN6N8 insulinoma cells
exposed to IFN-γ and TNF-α, resulting in an increase in
cytosolic Ca2+ concentration and activation of calpain and
calcineurin. Activated calcineurin mediates dephosphoryla-
tion of the proapoptotic protein BAD. Intracellular events
suchasmitochondrialdysfunctionandcaspaseactivationare
also involved in apoptosis of pancreatic β cell involving Ca2+
channel activation [46]. In addition, excessive production of
ROS, decrease in mitochondrial transmembrane potential,
activation of JNK/SAPK and P53 pathways, upregulation
of suppressor of cytokine signaling proteins (SOCS), and
activation of NF-κB and iNOS may also be involved in
the underlying mechanisms accounting for IFN-γ/TNF-α-
induced apoptosis of pancreatic β cells [47–49]. In vivo, the
decrease in circulating TNF-α level has been reported to be
involved in improvement of β-cell function of type 2 diabetic
patients receiving transient intensive insulin therapy [50].
3.Leptin
Since the discovery of adipocyte-derived hormone leptin
in 1994 [4], several other adipocyte-derived cytokines have
been identiﬁed. Leptin is one of the most important
cytokines secreted by adipose, and it plays vital roles in con-
trolling food intake and body energy balance [51]. Leptin-
or leptin-receptor-deﬁcient mice exhibit severe obesity and
diabetes [52]. Recently, leptin has been shown to directly
regulate insulin secretory process from pancreatic islets.
Leptin receptors have been shown to be expressed in rat islets
and murine-derived β-TC3 cells [53]. Covey and colleagues
reportthatmicewithdeletionofleptinreceptorinpancreatic
β cells and hypothalamus develop obesity, fasting hyperin-
sulinemia, impaired glucose-stimulated insulin release, and
glucose intolerance [54]. Morioka and colleagues further
conﬁrm that mice with speciﬁc disruption of leptin receptor
in pancreatic β cells develop more severe glucose intolerance
when fed a high-fat diet due to impaired insulin secretion
from β cells [55]. Consistently, we previously demonstrated
that electroporational transfer of naked plasmid with human
leptin gene into skeletal muscle of normal C57/B6 mice
leads to increased circulating leptin level and decreased
serum proinsulin level and fasting blood glucose [56].
Recently, Chen and colleagues have reported that overt type
2 diabetes in Akt1(+/−)Akt2(−/−)m i c ei sd u et om a r k e d l y
decreased leptin level and β-cell dysfunction. Hyperglycemia
of Akt1(+/−)Akt2(−/−) mice is signiﬁcantly attenuated by
restoring plasma leptin level concomitant with increased
circulatinginsulinlevel[57].Leptinhasalsobeenreportedto
prevent pancreatic β cells from inducible apoptosis, and this
may partially account for islet hypertrophy in obese rodents
and patients. Leptin may exert its antiapoptotic eﬀects on
pancreatic β cells by reducing triglyceride accumulation,
inhibiting NO production, increasing antiapoptotic protein
Bcl-2, and reducing apoptotic protein Bax [58–60]. Recent
ﬁndings indicate that IRS2-PI3K-Akt signaling axis plays a
crucial role in β-cell proliferation [61, 62]. Leptin suppresses
PTEN activity via CK2- (cyclin-dependent kinase-) depen-
dent pathways and results in an increase in PIP3 availability,
which activates PI3K/Akt signaling pathway in pancreatic
β cells [63]. All these results suggest that leptin has a
protectiveroleonpancreaticβcellsfunction.However,leptin
has also been shown to inhibit insulin secretion of β cells
via activation of ATP-regulated potassium (KATP) channels,
reduction in cellular cAMP level, and activation of PI3K-
dependent activation of cyclic nucleotide phosphodiesterase
3B (PDE3B) signaling pathway [64, 65]. Supportively,
Laubner and colleague show that leptin inhibits insulin
biosynthesis in pancreatic β cells by activating suppressor
of cytokine signaling 3 (SOCS3) [66, 67]. Leptin also sup-
presses acetylcholine-induced insulin secretion in isolated
perfused chicken pancreas [68] and induces the expression
of inﬂammatory genes in RINm5F insulinoma cells [69].
A recent study further indicates that mice with disrupted
leptin signaling in β cells display hyperinsulinemia, insulin
resistance, glucose intolerance, obesity, and reduced fasting
blood glucose. The authors further propose that insulin
resistance of these mice is due to excessive insulin secretion
from pancreatic β cells [70]. Central fusion of leptin directly
decreases insulin secretion capacity of pancreatic islets in rat
model [71]. In contrast to the controversial observations in
rodent models, leptin is likely to exert deleterious impact
on human islet function. A clinical study reveals that in
obese women after standardized weight reduction, improved
pancreatic β-cell function is independently associated with
the decreased leptin and increased adiponectin levels in
circulation [72]. In vitro, leptin decreases the expression of
IL-1ra and stimulates the release of IL-1β in human islets
[73]. Another study from the same group further indicates
that leptin impairs insulin secretion and induces apoptosis
of β cells in the presence of 20mM glucose via activation
of c-JNK in human islets [74]. Leptin also impairs insulin
secretion of human islets via inhibition of UPC2 expression
or increase in potassium channel permeability [75, 76].
Overall, leptin is likely to exert diverse eﬀects in regula-
tion of pancreatic β cell function, and further research is still
required to clarify its distinct role in various conditions.
4.Resistin
Resistin is another adipose-derived cytokine ﬁrst described
in 2001 [77]. Unlike the expression of resistin in mouse,
human resistin is expressed primarily in macrophages but
not in adipose [78]. Increased serum resistin level is asso-
ciated with insulin resistance in rodents and human. It has
been demonstrated that resistin impairs glucose tolerance
and antagonizes insulin action, indicating that resistin
may be an important cytokine linking obesity to diabetes
[77]. Treatment of diabetic mice with resistin-neutralizing4 International Journal of Endocrinology
antibodies signiﬁcantly ameliorates hyperglycemia of HFD-
fed mice [77]. Resistin increases β-cell viability at phys-
iological concentrations (10–20ng/mL) [79]. In contrast,
pretreatment of pancreatic β cells (β TC-6 or BRIN-BD11
cells) with pathological concentration of resistin (40ng/mL)
for 24 hours signiﬁcantly reduces insulin receptor expression
[79]. Resistin induces apoptosis of rat insulinoma cell
RINm5F at the concentration of 200ng/mL via activation
of caspase-3 and NF-κB, which can be blocked by TIMP-1,
an inhibitor of Metalloproteinase-1 [80]. When the plasma
concentration of resistin is elevated by adenoviral-mediated
delivery of resistin, mice exhibit impaired insulin secretion
in response to glucose. In vitro, pretreatment of pancreatic
islets with resistin augments insulin release at basal glucose
concentration (2.8mM) whereas inhibits insulin release at
stimulatory glucose concentration (8.3mM). The authors
further show that resistin impairs insulin secretion of islets
by inducing SOCS3 expression and inhibiting Akt phos-
phorylation [81]. Resistin is also expressed in human islets,
and its expression is upregulated in insulin-resistant status,
suggesting that islet-produced resistin may be involved in
the progression of β-cell dysfunction in insulin-resistant
condition [82]. Overall, increased circulating resistin level
in obese or insulin-resistant status impairs insulin secretion
from islets, resulting in deterioration of glucose homeostasis.
Targeting resistin may represent a novel therapeutic strategy
for islet dysfunction and type 2 diabetes.
5. Adiponectin
Adiponectin, also known as Acrp-30 (adipocyte comple-
ment-related protein of 30kDa), apM1 (adipose most abun-
dantgenetranscript1),AdipoQ,andGBP28(gelatin-binding
protein of 28kDa), is another adipose-derived cytokine. It is
one of the most abundant circulating proteins with a con-
centration greater than 5mg/mL [83]. Adiponectin protein
is composed of an N-terminal collagenous domain and a
C-terminal globular domain. In vivo, adiponectin exists in
full-length form or as globular fragment. Adiponectin in
plasma is in its full-length form [84]. Adiponectin exerts
its physiological functions by binding to two subtypes of
adiponectin receptors, which are designated as AdipoR1
and AdipoR2, respectively. AdipoR1 is abundantly expressed
in muscle, and AdipoR2 is mainly expressed in liver. The
demonstratedphysiologicalfunctionsofadiponectininclude
insulin-sensitizing, antiatherogenic, and anti-inﬂammatory
eﬀects [85]. Recently, there has been an increasing evi-
dence that adiponectin is also involved in the regulation
of pancreatic β-cell function. Plasma adiponectin level is
signiﬁcantlylowerintype2diabeticpatientswhencompared
w i t hc o n t r o ls u b j e c t s[ 86]. Lower plasma adiponectin level
is associated with pancreatic β-cell dysfunction in women
during pregnancy [87]. In Hispanic women with recent ges-
tational diabetes mellitus, a decline in β-cell compensation
for insulin resistance is associated with decreased circulating
adiponectin level [88]. Supportively, low plasma adiponectin
level has been reported to predict abnormal pancreatic
β-cell function in Chinese men [89]. Both AdipoR1 and
AdipoR2 have been shown to be functionally expressed in
human and rat pancreatic β cells, and their expression can
be upregulated by oleate (unsaturated fatty acid) but not
palmitate (saturated fatty acid) [90] .Ar e c e n ts t u d ys h o w s
that the expression of AdipoR2 in murine-derived β-cell
line NIT-1 cells is increased under acute hyperlipidemic
stress. In contrast, chronic hyperlipidemic stress signiﬁcantly
downregulatesAdipoR2inNIT-1cells,whichcanbereversed
by activation of peroxisome proliferator-activator receptor
α (PPARα)[ 91]. The expression of AdipoR1 is decreased,
whereas the expression of AdipoR2 remains unchanged in
the islets of ob/ob mice [92]. Pretreatment with adiponectin
prevents INS-1 cells from insulin secretion dysfunction and
apoptosis induced by inﬂammatory cytokines, free fatty
acids, and high glucose [93, 94]. Adiponectin augments
insulin secretion in islets from normal rat or HFD-treated
mice at high glucose concentrations [95, 96]. Brown and
colleagues report that globular adiponectin stimulates PDX-
1 expression by 450% and decreases LPL (lipoprotein
lipase) expression by 45% in rat β-cell line BRIN-BD11
cells [97]. In human islets, pretreatment with full-length
adiponectin induces phosphorylation of acetyl coenzyme A
carboxylase (ACC) without signiﬁcant impact on basal or
glucose-stimulated insulin secretion [98]. This suggests that
adiponectin may repress the synthesis of fatty acids and
prevent lipid deposition in human β cells. In the same study,
the authors also report that adiponectin fails to prevent
human islet cells from apoptosis induced by FFAs [98].
Overall, adiponectin is a positive regulator of pancreatic β
function and may be a putative target for treatment of islet
dysfunction and type 2 diabetes.
6.Visfatin
In 2005, visfatin mRNA was identiﬁed from the visceral fat
using diﬀerential display PCR technology [99]. Visfatin had
been previously identiﬁed as a pre-B-cell colony-enhancing
factor (PBEF) or nicotinamide phosphoribosyltransferase
(Nampt), a 52-kd cytokine expressed in lymphocytes. When
compared with wild-type mice (visfatin+/+), heterozygous
visfatin+/−mice show lower circulating visfatin level and
higher plasma glucose concentration [99]. In vitro, visfatin
enhances glucose uptake in 3T3-L1 preadipocytes and
suppresses gluconeogenesis in H4IIEC3 hepatocytes. The
authors further show that visfatin can mimic the eﬀects of
insulin by binding to the insulin receptor and activating
insulin signaling pathway [99]. Supportively, visfatin regu-
lates glucose uptake, cell proliferation, and type I collagen
production in human osteoblasts in an insulin-like manner
[100]. Serum visfatin level is elevated in patients with type
2 diabetes and decreased after intensive glycemic control
[101]. It is also reported that visfatin synthesis is increased
in adipose tissue under diabetic status, leading to activa-
tion of NF-κB and systemic inﬂammation [102]. Revollo
and colleagues report that Nampt (visfatin) heterozygous
(Nampt+/−) mice show impaired glucose tolerance and
reduced glucose-stimulated insulin secretion, suggesting that
visfatin may be involved in regulation of insulin secretion in
β cells. Controversially, the authors fail to observe its insulin-
mimetic eﬀects [103, 104] such as inducing preadipocyteInternational Journal of Endocrinology 5
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Figure 1: Cytokines play important roles in regulation of pancreatic β-cell function. The disturbed balance of deleterious and protective
cytokines in islets and plasma plays crucial roles in the development and progression of β-cell dysfunction and type 2 diabetes.
diﬀerentiation, activation of insulin receptor and Akt, as
previously reported [99]. Furthermore, visfatin also fails
to stimulate glucose transport and mimic the lipolysis
inhibition eﬀect of insulin in human adipocyte [105]. Brown
and colleagues report that visfatin upregulates the mRNA
expressionofinsulin(9-foldtocontrol)andenhancesinsulin
secretion by 46% in murine-derived β-TC6 cells at low
glucose. These eﬀects of visfatin can be blocked by FK866, a
speciﬁc inhibitor of Nampt [106]. Overall, visfatin may have
protective eﬀect on pancreatic β-cell function, but further
research is required to clarify its distinct roles.
7.PANcreatic DERivedFactor
(PANDER, FAM3B)
PANDER (PANcreatic DERived factor, FAM3B) is a novel
cytokine that has been recently cloned and identiﬁed using
an algorithm, ostensible recognition of folds (ORF), search-
ing for novel cytokines based on their predicted secondary
structure [11]. The rationale for this approach is that the
secondary structure of cytokines is highly conserved through
evolution. Many cytokines are four-helix bundles with disul-
ﬁde bridges. This approach has allowed the identiﬁcation
of a novel cytokine family consisting of 4 members: 2–19
(FAM3A), EF-7 (FAM3D), FAM3C, and FAM3B in 2002.
Northern blot and immunohistochemical assays reveal
that FAM3B is highly expressed in pancreatic islets [11].
FAM3B is thus also called PANcreatic DERived factor
(PANDER) in subsequent studies [7]. PANDER is a 235-
amino acid protein with a secretion signal peptide [11].
In vitro, we have demonstrated that recombinant PANDER
pretreatment or viral-mediated overexpression of PANDER
inhibits insulin secretion and induces pancreatic β-cell
apoptosis of rodent and human islets [7, 8, 107]. IFN-γ
has been shown to regulate PANDER expression in mouse
islets in a dose- and time-dependent manner, suggesting that
PANDER may be involved in IFN-γ-mediated apoptosis of
islet β cells [108]. Furthermore, glucose potently activates
the PANDER promoter activity in primary pancreatic islets
and β-cell lines [101, 109]. More recently, Burkhardt and
colleagues report that the PANDER promoter activity is
also regulated by PDX-1, conﬁrming that the expression of
PANDER is regulated in a manner similar to insulin in islets
[110]. These observations have suggested that PANDER may
have a potential role in the regulation of β-cell function and
glucose homeostasis as a locally produced cytokine in islets.
In addition, PANDER protein is cosecreted with insulin
from pancreatic β cells through a similar Ca2+-dependent
regulatory mechanisms [9], suggesting that PANDER may
also act on other tissues or cells as an endocrine factor.
To identify the target tissues of PANDER, the in vitro 125I-
PANDER saturation and competitive binding assays have
beenperformedusingtissuemembranes.Thebindingresults
indicate that PANDER speciﬁcally binds to the liver cell
membrane. Cross-linking experiments further conﬁrm that
PANDER interacts with some unknown protein on the liver
membrane. In contrast, PANDER does not bind to the
membrane of pancreas, muscle, kidney, and heart [111].
In HepG2 cells, PANDER pretreatment signiﬁcantly inhibits
insulin-stimulated activation of IR, IRS-1, PI3K, and Akt.
These observations have suggested that liver is a novel target
for islet-secreted PANDER. In addition, PANDER fails to
induce cell apoptosis of HepG2 cells. The physiological role
of PANDER is to some extent similar to that of amylin,
also known as islet amyloid polypeptide (IAPP). Amylin is
anotherislet-speciﬁcproteinwhichiscosecretedwithinsulin
from β cells [112]. Normally, amylin inhibits glucagon
secretion, delays gastric emptying, and inhibits food intake
[113]. However, chronic hyperglycemia stimulates amylin
production in insulin-resistant condition. Excessive amylin
will be deposited as amyloid in islets and will result in
isletdysfunction[114,115].Interestingly,PANDER-deﬁcient
mice show glucose intolerance due to impaired insulin secre-
tion from pancreatic β cells [116]. Because the expression
and secretion of PANDER is similarly regulated by glucose
as insulin, it is reasonable to speculate that PANDER may6 International Journal of Endocrinology
regulate insulin secretion process [9, 109, 110, 116, 117]. In
addition, pancreatic α cells also secrete PANDER in response
to L-arginine and insulin [118].
Overall, chronic hyperglycemia and compensatory
increase in insulin secretion ability of pancreatic β cells
and islet hypertrophy may result in increased production
of PANDER in islets. Excessive PANDER may negatively
regulate islet function as a local cytokine and deteriorate
hepatic glucose metabolism as an endocrine factor. Clearly,
PANDER may be a novel linker between insulin resistance
(prediabetes) and type 2 diabetes.
8.SummaryandPerspective
It is likely that crosstalk among cytokines in islets or other
tissues may also be widely involved in regulation of pan-
creatic β-cell function. For example, TNF-α neutralization
increases circulating adiponectin level and decreases resistin
level in patients with the metabolic syndrome [119]. Leptin
represses resistin expression in adipose [120]. Leptin also
decreases IL-1ra expression and increases IL-1β release in
islets [73, 120]. IFN-γ upregulates PANDER expression in β
cells [108]. Insulin regulates the expression and secretion of
various cytokines in islets and adipose, which may in return
regulate insulin secretion from islets [118, 121–123].
Overall, cytokines are widely involved in the regulation
of pancreatic β-cell function. In insulin-resistant status, the
levels of deleterious cytokine in islet β cells and plasma
increase, whereas the levels of protective cytokines decrease.
Thisabnormalchangeinlocalandcirculatingcytokinesplays
an important role in triggering β-cell dysfunction and type 2
diabetes (Figure 1). Restoring the normal cytokine proﬁle in
β cells and plasma may hold great promise for treatment of
β-cell dysfunction and type 2 diabetes.
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